Thinking under the trend of digital transformation of traditional pharmaceutical enterprises

"Pharmaceutical Network Market Analysis" November 2 news, Huawei and Hubei People Fu Pharmaceutical Group and Wuhan Defa Electronic Information jointly signed a cooperation agreement, Huawei will provide products and solutions, Defa is responsible for delivery of security, the three-way strong joint, to help Hubei People Fu Pharmaceutical Group towards digital transformation and upgrading.
china's pharmaceutical market is maintaining a high-speed growth trend.
china's pharmaceutical market has grown from 955.5 billion yuan in 2012 to 2150 billion yuan in 2020, with a compound annual growth rate of 10.7%, according to The New Year.
overall, the pharmaceutical industry is still dominated by traditional medicine.
This year, affected by the special period, cloud, big data and other new technologies brought about by the value of more prominent, coupled with generic drug consistency evaluation, drug collection and other pharmaceutical New Deal, the industry generally recognized that the digital transformation of medicine has become the trend.
digital transformation of traditional enterprises is imperative.
To this end, in May this year 17 ministries also jointly launched the "Digital Transformation Partnership Action (2020)," which for small and medium-sized enterprises face the lack of capacity "will not turn", high costs "cannot turn", long pain period "dare not turn" and other issues, Encourage the convergence of the whole society to promote the implementation of partner actions by creating a good atmosphere, creatively propose to create a "virtual industrial park" and "virtual industrial cluster" across the physical boundaries, break the geographical limitations, but also to achieve a one-time investment, multiple reuse, effectively reduce the cost of digital transformation of enterprises.
this time Huawei is a positive response to the "digital transformation partner action" to help traditional pharmaceutical companies "on the cloud" transformation and upgrading.
in the industry, traditional enterprise digital transformation will not happen overnight, in the short term through digital transformation partner action, can help some enterprises to ease order and supply chain pressure, reduce operating costs.
the medium to long term, in the context of accelerating the promotion of new infrastructure projects in various places, the digital transformation partnership action will help to play the role of digital economy traction, stimulate the endo-dynamics of digital transformation of enterprises, and empower China's high-quality economic development.
, drug companies have been actively accelerating their digital wave this year.
, such as GSK, Roche and other traditional large pharmaceutical companies have accelerated the process of digital transformation.
Among them, GSK Consumer Health Products announced in September that it had signed JBP with Mother Ali to promote digital transformation, and Roche Group, as a global biotechnology and digital health care practitioner, has obvious expertise in managing, integrating and analyzing big data on health, and has practical experience in the successful use of big data at all stages of the industrial chain. Dr. Severin Schwan, ceo of
Global CEO, said at the 32nd Shanghai Mayor's International Entrepreneurs Advisory Conference on Cloud Attendance that in the future, Roche will continue to take advantage of digital innovation and support the transformation and upgrading of China's healthcare industry.
compared with foreign pharmaceutical companies, the digital transformation of domestic pharmaceutical companies has only just begun.
Industry pointed out that the current digital transformation of domestic pharmaceutical companies is still in the initial stage, mature model is relatively small, but more and more traditional pharmaceutical companies have realized the importance of digital transformation, I believe that in the future there will be more traditional pharmaceutical companies in the digital transformation into a butterfly.
For those traditional pharmaceutical companies that have not yet dabbled in digitalization or have not yet carried out large-scale digital transformation of pharmaceutical companies, some industry people believe that the digitalization of pharmaceutical companies involves many links, it is difficult to do it alone, the need to work with upstream and downstream partners.
Suggests this: first, to set a clear top-down strategy within the team, second, to build a relatively experienced team to avoid detours, and third, to find a reliable external partner to work together to advance the digital transformation path.